| Literature DB >> 31431620 |
N Alcala1, N Leblay1, A A G Gabriel1, L Mangiante1, D Hervas2, T Giffon1, A S Sertier3, A Ferrari3, J Derks4, A Ghantous5, T M Delhomme1, A Chabrier1, C Cuenin5, B Abedi-Ardekani1, A Boland6, R Olaso6, V Meyer6, J Altmuller7, F Le Calvez-Kelm1, G Durand1, C Voegele1, S Boyault8, L Moonen4, N Lemaitre9, P Lorimier9, A C Toffart10, A Soltermann11, J H Clement12, J Saenger13, J K Field14, M Brevet15, C Blanc-Fournier16, F Galateau-Salle17, N Le Stang17, P A Russell18, G Wright18, G Sozzi19, U Pastorino19, S Lacomme20, J M Vignaud20, V Hofman21, P Hofman21, O T Brustugun22,23, M Lund-Iversen23, V Thomas de Montpreville24, L A Muscarella25, P Graziano25, H Popper26, J Stojsic27, J F Deleuze6, Z Herceg5, A Viari3, P Nuernberg7,28, G Pelosi29, A M C Dingemans4, M Milione19, L Roz19, L Brcic26, M Volante30, M G Papotti30, C Caux31, J Sandoval2, H Hernandez-Vargas32, E Brambilla9, E J M Speel4, N Girard33,34, S Lantuejoul3,8,17, J D McKay1, M Foll1, L Fernandez-Cuesta35.
Abstract
The worldwide incidence of pulmonary carcinoids is increasing, but little is known about their molecular characteristics. Through machine learning and multi-omics factor analysis, we compare and contrast the genomic profiles of 116 pulmonary carcinoids (including 35 atypical), 75 large-cell neuroendocrine carcinomas (LCNEC), and 66 small-cell lung cancers. Here we report that the integrative analyses on 257 lung neuroendocrine neoplasms stratify atypical carcinoids into two prognostic groups with a 10-year overall survival of 88% and 27%, respectively. We identify therapeutically relevant molecular groups of pulmonary carcinoids, suggesting DLL3 and the immune system as candidate therapeutic targets; we confirm the value of OTP expression levels for the prognosis and diagnosis of these diseases, and we unveil the group of supra-carcinoids. This group comprises samples with carcinoid-like morphology yet the molecular and clinical features of the deadly LCNEC, further supporting the previously proposed molecular link between the low- and high-grade lung neuroendocrine neoplasms.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31431620 PMCID： PMC6702229 DOI： 10.1038/s41467-019-11276-9
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919